{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:48:40Z","timestamp":1767901720467,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40262-025-01586-1","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:11:28Z","timestamp":1762179088000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-4410","authenticated-orcid":false,"given":"Pier Giorgio","family":"Cojutti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale Maria","family":"Berrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Rotaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Schiavina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Brunocilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"1","key":"1586_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1464-410X.2011.10250.x","volume":"109","author":"SP Stroup","year":"2012","unstructured":"Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int. 2012;109(1):84\u20137.","journal-title":"BJU Int"},{"issue":"4","key":"1586_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/01.ju.0000155709.37840.fe","volume":"173","author":"JT Wei","year":"2005","unstructured":"Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256\u201361.","journal-title":"J Urol"},{"issue":"1","key":"1586_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MOU.0b013e32834d8e87","volume":"22","author":"AA Juliao","year":"2012","unstructured":"Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. Curr Opin Urol. 2012;22(1):34\u20139.","journal-title":"Curr Opin Urol"},{"issue":"4","key":"1586_CR4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J Urol. 2021;206(4):806\u201317.","journal-title":"J Urol"},{"issue":"1","key":"1586_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5213\/inj.1732640.320","volume":"21","author":"MJ Woo","year":"2017","unstructured":"Woo MJ, Ha YS, Lee JN, Kim BS, Kim HT, Kim TH, et al. Comparison of surgical outcomes between holmium laser enucleation and transurethral resection of the prostate in patients with detrusor underactivity. Int Neurourol J. 2017;21(1):46\u201352.","journal-title":"Int Neurourol J"},{"issue":"1","key":"1586_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000343549","volume":"7","author":"CV Bishop","year":"2013","unstructured":"Bishop CV, Liddell H, Ischia J, Paul E, Appu S, Frydenberg M, et al. Holmium laser enucleation of the prostate: comparison of immediate postoperative outcomes in patients with and without antithrombotic therapy. Curr Urol. 2013;7(1):28\u201333.","journal-title":"Curr Urol"},{"issue":"1","key":"1586_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","volume":"86","author":"J Kranz","year":"2024","unstructured":"Kranz J, Bartoletti R, Bruy\u00e8re F, Cai T, Geerlings S, K\u00f6ves B, et al. European association of urology guidelines on urological infections: summary of the 2024 guidelines. Eur Urol. 2024;86(1):27\u201341.","journal-title":"Eur Urol"},{"issue":"2","key":"1586_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000509","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203(2):351\u20136.","journal-title":"J Urol"},{"key":"1586_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jgar.2020.10.020","volume":"23","author":"IA Critchley","year":"2020","unstructured":"Critchley IA, Cotroneo N, Pucci MJ, Jain A, Mendes RE. Resistance among urinary tract pathogens collected in Europe during 2018. J Glob Antimicrob Resist. 2020;23:439\u201344.","journal-title":"J Glob Antimicrob Resist"},{"issue":"12","key":"1586_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265","volume":"14","author":"IA Critchley","year":"2019","unstructured":"Critchley IA, Cotroneo N, Pucci MJ, Mendes R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS\u00a0One. 2019;14(12):e0220265.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"1586_CR11","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/cid\/cit704","volume":"58","author":"BJ Gardiner","year":"2014","unstructured":"Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101\u20135.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1586_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000342370","volume":"89","author":"S Ong\u00fcn","year":"2012","unstructured":"Ong\u00fcn S, Aslan G, Avkan-Oguz V. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int. 2012;89(4):439\u201344.","journal-title":"Urol Int"},{"issue":"Suppl 2","key":"1586_CR13","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1007\/BF01643437","volume":"18","author":"L Baert","year":"1990","unstructured":"Baert L, Billiet I, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection. 1990;18(Suppl 2):S103\u20136.","journal-title":"Infection"},{"issue":"Suppl 1","key":"1586_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000472877","volume":"13","author":"P Periti","year":"1987","unstructured":"Periti P, Novelli A, Reali EF, Lamanna S, Fontana P. Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial. Eur Urol. 1987;13(Suppl 1):122\u201331.","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"1586_CR15","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1007\/BF01643436","volume":"18","author":"F di Silverio","year":"1990","unstructured":"di Silverio F, Ferrone G, Carati L. Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study. Infection. 1990;18(Suppl 2):S98-102.","journal-title":"Infection"},{"issue":"2","key":"1586_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","volume":"35","author":"T Cai","year":"2017","unstructured":"Cai T, Gallelli L, Cocci A, Tiscione D, Verze P, Lanciotti M, et al. Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol. 2017;35(2):221\u20138.","journal-title":"World J Urol"},{"issue":"5","key":"1586_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/antibiotics13050424","volume":"13","author":"PM Berrino","year":"2024","unstructured":"Berrino PM, Gatti M, Rotaru V, Bianchi L, Tumietto F, Sora E, et al. Efficacy of a novel prophylactic scheme of fosfomycin trometamol in patients undergoing endoscopic surgery for benign prostatic hyperplasia: findings from a prospective monocentric single-arm study. Antibiotics (Basel). 2024;13(5):424.","journal-title":"Antibiotics (Basel)."},{"issue":"6","key":"1586_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1128\/AAC.32.6.938","volume":"32","author":"F Borsa","year":"1988","unstructured":"Borsa F, Leroy A, Fillastre JP, Godin M, Moulin B. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrob Agents Chemother. 1988;32(6):938\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1586_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/FTD.0000000000001158","volume":"46","author":"R Barone","year":"2024","unstructured":"Barone R, Conti M, Giorgi B, Gatti M, Cojutti PG, Viale P, et al. Fast and sensitive analysis of fosfomycin in human plasma microsamples using liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring. Ther Drug Monit. 2024;46(3):384\u201390.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1586_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/pharmaceutics16050681","volume":"16","author":"M Conti","year":"2024","unstructured":"Conti M, Giorgi B, Barone R, Gatti M, Cojutti PG, Pea F. A sensitive liquid chromatography-tandem mass spectrometry method for measuring fosfomycin concentrations in human prostatic tissue. Pharmaceutics. 2024;16(5):681.","journal-title":"Pharmaceutics"},{"issue":"9","key":"1586_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1586_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40268-018-0241-0","volume":"18","author":"R Dimelow","year":"2018","unstructured":"Dimelow R, Wright JG, MacPherson M, Newell P, Das S. Population pharmacokinetic modelling of Ceftazidime and Avibactam in the plasma and epithelial lining fluid of healthy volunteers. Drugs R D. 2018;18(3):221\u201330.","journal-title":"Drugs R D"},{"issue":"3","key":"1586_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/AAC.20.3.393","volume":"20","author":"M Goto","year":"1981","unstructured":"Goto M, Sugiyama M, Nakajima S, Yamashina H. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob Agents Chemother. 1981;20(3):393\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1586_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00476-17","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, et al. Pharmacokinetics and pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(6):10\u20131118.","journal-title":"Antimicrob Agents Chemother"},{"key":"1586_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijid.2016.06.017","volume":"50","author":"O Asuphon","year":"2016","unstructured":"Asuphon O, Montakantikul P, Houngsaitong J, Kiratisin P, Sonthisombat P. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic\/pharmacodynamic (PK\/PD) simulation. Int J Infect Dis. 2016;50:23\u20139.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"1586_CR26","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/jac\/dkh158","volume":"53","author":"B Pfausler","year":"2004","unstructured":"Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004;53(5):848\u201352.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1586_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/jac\/dkg187","volume":"51","author":"C Joukhadar","year":"2003","unstructured":"Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother. 2003;51(5):1247\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"1586_CR28","unstructured":"EUCAST. 2024. MIC distributions and ECOFFs. https:\/\/www.eucast.org\/mic_distributions_and_ecoffs\/. Accessed 30 Apr 2025."},{"issue":"10","key":"1586_CR29","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1128\/AAC.01321-15","volume":"59","author":"SL Parker","year":"2015","unstructured":"Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59(10):6471\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"1586_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000472864","volume":"13","author":"G Segre","year":"1987","unstructured":"Segre G, Bianchi E, Cataldi A, Zannini G. Pharmacokinetic profile of fosfomycin trometamol (Monuril). Eur Urol. 1987;13(Suppl 1):56\u201363.","journal-title":"Eur Urol"},{"issue":"11","key":"1586_CR31","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/antibiotics11111458","volume":"11","author":"AFD Di Stefano","year":"2022","unstructured":"Di Stefano AFD, Radicioni MM, Morano F, Gentili A, Mallat E, Cuomo D, et al. Fosfomycin pharmacokinetic profile in plasma and urine and quantitative estimation in prostate and seminal vesicles after one and two consecutive doses of oral fosfomycin trometamol in healthy male volunteers. Antibiotics (Basel). 2022;11(11):1458.","journal-title":"Antibiotics (Basel)."},{"key":"1586_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-18","author":"E Wenzler","year":"2018","unstructured":"Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, et al. Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00464-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1586_CR33","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/jac\/dkv067","volume":"70","author":"NJ Rhodes","year":"2015","unstructured":"Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, et al. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother. 2015;70(7):2068\u201373.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"1586_CR34","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.1007\/BF01710024","volume":"20","author":"FP Selvaggi","year":"1992","unstructured":"Selvaggi FP, Battaglia M, Grossi FS, Disabato G, Cormio L. Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience. Infection. 1992;20(Suppl 4):S321\u20134.","journal-title":"Infection"},{"issue":"12","key":"1586_CR35","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1128\/AAC.04955-14","volume":"59","author":"BD VanScoy","year":"2015","unstructured":"VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, et al. Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model. Antimicrob Agents Chemother. 2015;59(12):7170\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1586_CR36","volume":"2018","author":"J Wang","year":"2018","unstructured":"Wang J, He JT, Bai Y, Wang R, Cai Y. Synergistic activity of colistin\/fosfomycin combination against carbapenemase-producing. Biomed Res Int. 2018;2018:5720417.","journal-title":"Biomed Res Int"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01586-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:31:02Z","timestamp":1767886262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01586-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pier Giorgio Cojutti has received a grant from Angelini and Shionogi, outside of the submitted work. Pierluigi Viale has served as a consultant for Advanz Pharma, Angelini, bioM\u00e9rieux, Gilead, Merck Sharp & Dohme, InfectoPharm, Pfizer, Shionogi, Thermo-Fisher, Venatorx, and Viatris and served on the speaker\u2019s bureau for Advanz Pharma, Angelini, Gilead, Merck Sharp & Dohme, InfectoPharm, Menarini, Pfizer, Shionogi, and Viatris outside the submitted work. Federico Pea has served as a consultant for Advanz Pharma, Angelini, Gilead, Merck Sharp & Dohme, Pfizer, and Viatris outside the submitted work and participated on speaker\u2019s bureaus for Angelini, Gilead, Menarini, Merck Sharp & Dohme, InfectoPharm, Pfizer, Shionogi, and Viatris outside of the submitted work. Federico Pea is an editorial board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the Declaration of Helsinki guidelines and approved by the local ethics committee (no. 882\/2021\/Oss\/AOUBo on 31 January 2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed written consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants agreed to the publication policy as per study protocol.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data presented in this study are available upon request from the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The population pharmacokinetic codes are available in the electronic supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the concept and interpretation of the study. PGC performed the study and curated and analyzed the data. PGC and FP wrote the original manuscript. FP, PV, and EB designed the research and supervised the study. PB, VR, LB, and RS reviewed and commented on the manuscript. All authors read and agreed to the published version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}